Clinical advances in later-line therapy for metastatic or refractory colorectal cancer
World Journal of Gastroenterology · 2027-01-14 · 33 (2)
DOI: 10.3748/wjg.123996 ↗Abstract
Metastatic colorectal cancer still ranks among the leading causes of cancer-related death globally owing to its poor treatment response. For patients with progression after first-line therapy, especially those with microsatellite-stable/proficient mismatch repair tumors or tumors harboring BRAF V600E or KRAS G12C mutations, high-quality evidence for optimal therapies remains scarce. This review summarizes clinical studies from the past 5 years on second-line and subsequent therapies for metastatic colorectal cancer, covering optimized combinations of chemotherapy, targeted therapy, immunotherapy, and radiotherapy, along with evaluations of novel agents. A review of these clinical advances reveals that chemotherapy regimens based on raltitrexed or trifluridine/tipiracil hydrochloride mixture (TAS-102) have demonstrated favorable efficacy in patients with fluoropyrimidine resistance. Antiangiogenic agents, epidermal growth factor receptor/human epidermal growth factor receptor 2/mesenchymal-epithelial transition factor blockade, BRAF inhibitors, and KRAS G12C inhibitors prolong survival. Immunotherapy yields durable responses in microsatellite instability-high/deficient mismatch repair metastatic colorectal cancer, especially with dual immune checkpoint inhibition. Combinations of drugs with different mechanisms of action may treat refractory microsatellite-stable/proficient mismatch repair disease. Novel antibody-drug conjugates and other antitumor agents offer new options for previously treated patients. Limited high-quality evidence hinders optimal regimen selection. Future work should focus on improving individualized therapy and multidisciplinary management.
EUVIMED